A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

No nail changes were noted. His grandfather has a history of psoriasis. Guttate psoriasis mainly affects the trunk and proximal extremities, but may be generalized in distribution. Lesions may ...

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

Guttate psoriasis, from the Latin for “raindrop shaped,” causes small, dot-like spots on the body. These lesions frequently appear on the upper arms, trunk, thighs, or scalp. Often ...

Otezla, a first-in-class treatment for plaque psoriasis has been approved in the US. Celgene's drug Otezla (apremilast) is an oral, selective inhibitor of phosphodiesterase 4 (PDE4) and gained its ...

May 27, 2025 — Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

The usual maintenance dosage of Otezla (apremilast) is two 30-mg doses per day. It’s important to take the Otezla dosage your doctor prescribes. Otezla belongs to a class of drugs called disease ...

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

Roflumilast foam 0.3% applied once daily led to significantly greater clearance of scalp and body plaque psoriasis lesions and more rapid itch reduction than placebo over eight weeks.

77% of genital psoriasis patients saw clear/almost clear skin vs. 21% on placebo after 16 weeks. PN-881 showed 70x greater potency than secukinumab in vitro and effective reduction in skin ...

Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents due to an ability to regulate inflammatory signaling pathways.